financetom
Business
financetom
/
Business
/
BeiGene to Rename as BeOne Medicines
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BeiGene to Rename as BeOne Medicines
Nov 15, 2024 12:44 PM

07:08 AM EST, 11/14/2024 (MT Newswires) -- BeiGene ( BGNE ) said Thursday it plans to change its name to BeOne Medicines, subject to shareholder approval.

Once the name change is approved, the company's Nasdaq ticker will change to "ONC."

The name change is part of the company's global oncology growth strategy.

Price: 222.99, Change: -4.06, Percent Change: -1.79

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Globalstar to Expand its Satellite Communications Network
Globalstar to Expand its Satellite Communications Network
Sep 15, 2025
08:03 AM EDT, 09/15/2025 (MT Newswires) -- Globalstar ( GSAT ) said Monday it is planning to bring into use its new HIBLEO-XL-1 satellite system. The company, which has been operating its current mobile satellite system over big low-earth-orbit frequency bands, said last year that it was investing $1.5 billion in a new mobile satellite system that will include 48...
dynaCERT Names John Amodeo as CFO
dynaCERT Names John Amodeo as CFO
Sep 15, 2025
08:03 AM EDT, 09/15/2025 (MT Newswires) -- dynaCERT (DYA.TO) earlier Monday said it appointed John Amodeo as chief financial officer, effective immediately. Amodeo recently joined the company's board and continues to serve as a member of the board. He has served as chair of dynaCERT's audit committee since his appointment. The company said Amodeo resigned from his position as audit...
aTyr Pharma's Phase 3 Trial of Lung Disease Treatment Misses Primary Endpoint
aTyr Pharma's Phase 3 Trial of Lung Disease Treatment Misses Primary Endpoint
Sep 15, 2025
08:05 AM EDT, 09/15/2025 (MT Newswires) -- aTyr Pharma ( ATYR ) reported Monday that a phase 3 study of efzofitimod to treat pulmonary sarcoidosis, a type of lung disease, missed its primary endpoint. The study's primary endpoint was the change from baseline in mean daily oral corticosteroid dose at week 48. The biotech company said it will seek a...
Artemis Gold to Spend Up to $110 Million to Boost Blackwater Mine Phase-One Capacity by 33%
Artemis Gold to Spend Up to $110 Million to Boost Blackwater Mine Phase-One Capacity by 33%
Sep 15, 2025
08:06 AM EDT, 09/15/2025 (MT Newswires) -- Artemis Gold ( ARGTF ) said Monday it will invest $100 million to $110 million to expand phase-one processing capacity at its Blackwater mine in British Columbia. The upgrade will increase the phase-one processing plant's nameplate capacity by 33% to 8 million tonnes per year from 6 million tonnes, the company said. We...
Copyright 2023-2026 - www.financetom.com All Rights Reserved